Logo image of ADOC.PA

ADOCIA SAS (ADOC.PA) Stock Price, Forecast & Analysis

Europe - Euronext Paris - EPA:ADOC - FR0011184241 - Common Stock

6.05 EUR
-0.06 (-0.98%)
Last: 1/16/2026, 7:00:00 PM

ADOC.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap110.78M
Revenue(TTM)10.35M
Net Income(TTM)-9.72M
Shares18.31M
Float15.58M
52 Week High12.4
52 Week Low2.86
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.56
PEN/A
Fwd PEN/A
Earnings (Next)02-24
IPO2012-02-20
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
ADOC.PA short term performance overview.The bars show the price performance of ADOC.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40

ADOC.PA long term performance overview.The bars show the price performance of ADOC.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40

The current stock price of ADOC.PA is 6.05 EUR. In the past month the price decreased by -7.91%. In the past year, price decreased by -4.27%.

ADOCIA SAS / ADOC Daily stock chart

ADOC.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ADOC.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ADOC.PA. Both the profitability and financial health of ADOC.PA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ADOC.PA Financial Highlights

Over the last trailing twelve months ADOC.PA reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 63.52% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -35.67%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%13.8%
Sales Q2Q%N/A
EPS 1Y (TTM)63.52%
Revenue 1Y (TTM)1879.16%

ADOC.PA Forecast & Estimates

9 analysts have analysed ADOC.PA and the average price target is 15.5 EUR. This implies a price increase of 156.26% is expected in the next year compared to the current price of 6.05.

For the next year, analysts expect an EPS growth of -91.44% and a revenue growth -51.75% for ADOC.PA


Analysts
Analysts84.44
Price Target15.5 (156.2%)
EPS Next Y-91.44%
Revenue Next Year-51.75%

ADOC.PA Ownership

Ownership
Inst Owners12.54%
Ins Owners3.53%
Short Float %N/A
Short RatioN/A

ADOC.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ARGX.BR ARGENX SE 64.82 42.92B
1AE.DE ARGENX SE 64.86 42.73B
22UA.DE BIONTECH SE-ADR N/A 22.67B
2X1.DE ABIVAX SA N/A 8.03B
ABVX.PA ABIVAX SA N/A 8.02B
GXE.DE GALAPAGOS NV N/A 1.92B
GLPG.AS GALAPAGOS NV N/A 1.91B
IVA.PA INVENTIVA SA N/A 1.09B
6IV.DE INVENTIVA SA N/A 967.31M
NANO.PA NANOBIOTIX N/A 891.02M
PHIL.MI PHILOGEN SPA 19.12 637.43M
FYB.DE FORMYCON AG N/A 424.96M

Related stock screener links

About ADOC.PA

Company Profile

ADOC logo image Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 77 full-time employees. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.

Company Info

ADOCIA SAS

115 avenue Lacassagne

Lyon AUVERGNE-RHONE-ALPES FR

Employees: 76

ADOC Company Website

ADOC Investor Relations

Phone: 33472610610

ADOCIA SAS / ADOC.PA FAQ

What does ADOC do?

Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 77 full-time employees. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.


What is the stock price of ADOCIA SAS today?

The current stock price of ADOC.PA is 6.05 EUR. The price decreased by -0.98% in the last trading session.


What is the dividend status of ADOCIA SAS?

ADOC.PA does not pay a dividend.


How is the ChartMill rating for ADOCIA SAS?

ADOC.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the sector and industry classification for ADOCIA SAS?

ADOCIA SAS (ADOC.PA) operates in the Health Care sector and the Biotechnology industry.


What is the market capitalization of ADOC stock?

ADOCIA SAS (ADOC.PA) has a market capitalization of 110.78M EUR. This makes ADOC.PA a Micro Cap stock.